Cancer clinical trials in the region Auvergne-Rhône-Alpes

412 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account
and find trials relevant to your profile

Phase 2 Colon cancer Rectal cancer Stomach and esophageal cancer #NCT06245356 #2023-508724-35-00

[TRIFLUOX-DP] Innocuité de la TRIFLURIDINE/TIPIRACIL chez les patients présentant un déficit en dihydropyrimidine déshydrogénase diagnostiqué avec un cancer colorectal ou gastro-œsophagien métastatique

Stomach Oesogastric junction Esophagus Adenocarcinoma Metastatic None Systemic Treatment-Naive

Hôpital Privé Jean Mermoz - Ramsay Santé (Lyon)

UNICANCER

Phase 2 Lymphoma CLL & Richter's syndrome #NCT04728893 #2023-504931-42-00

[MK-1026-003] Efficacité et innocuité du NEMTABRUTINIB (MK-1026) chez les participants atteints d'hémopathies malignes - Cohortes A à C et J

B cell lymphoma CLL (Chronic Lymphocytic Leukemia) Lymphocytic lymphoma None Treated / Controled 1 2 3 or more

Systemic Treatment-Naive

Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite)

Merck Sharp & Dohme LLC

Phase 2 Lymphoma #NCT04728893 #2023-504931-42-00

[MK-1026-003] Efficacité et innocuité du NEMTABRUTINIB (MK-1026) chez les participants atteints d'hémopathies malignes Cohorte H

B cell lymphoma Waldenström lymphoma None Treated / Controled 1 2 3 or more Chemotherapy Targeted therapy Monoclonal antibodies

Systemic Treatment-Naive

Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite)

Merck Sharp & Dohme LLC

Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT06660654 #2024-513307-13-00

[REJOICE-PanTumor01] Étude du RALUDOTATUG DERUXTECAN chez des participants atteints de tumeurs solides avancées/métastatiques

Invasive bladder cancer Upper excretory tract cancer Urethral cancer Locally Advanced Metastatic 1 2 3 or more Immunotherapy

Systemic Treatment-Naive

Centre Léon Bérard (Lyon)

Daiichi Sankyo

Phase 2 Endometrial cancer #NCT06660654 #2024-513307-13-00

[REJOICE-PanTumor01] Étude du RALUDOTATUG DERUXTECAN chez des participants atteints de tumeurs solides avancées/métastatiques

Locally Advanced Metastatic 1 2 3 or more Immunotherapy Chemotherapy

Systemic Treatment-Naive

Centre Léon Bérard (Lyon)

Daiichi Sankyo

Phase 2 Lung cancer #NCT05732831 #2022-502645-99-00

Innocuité et tolérance du TNG462 chez les patients atteints de tumeurs solides avec suppression du gène MTAP

SCLC (Small Cell Lung Cancer) NSCLC (Non-Small Cell Lung Cancer) Mesothelium Locally Advanced Metastatic MTAP 1 2 3 or more

Systemic Treatment-Naive

Centre Léon Bérard (Lyon)

Tango Therapeutics

Phase 2 Lymphoma #NCT05963074 #2023-504044-34-00

[TAILOR] Étude visant à personnaliser les schémas thérapeutiques à base d'IBRUTINIB pour les participants atteints de leucémie lymphoïde chronique/lymphome lymphocytaire à petits lymphocytes non traités auparavant

B cell lymphoma Lymphocytic lymphoma None None Systemic Treatment-Naive

Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite)

Janssen

Phase 2 Breast cancer #NCT05215106 #2024-512082-14-00

[POP-DURVA] Étude du DURVALUMAB (MEDI 4736) préopératoire de courte durée chez des patientes atteintes d'un cancer du sein triple négatif de petite taille

HER2 Negative HR Negative Localized None Systemic Treatment-Naive

Surgery Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC) Radiotherapy

Centre Léon Bérard (Lyon)

Gustave Roussy, Campus du cancer, Grand Paris

Phase 2 Lung cancer #NCT05609578 #2023-503714-77-00

Essai de phase 2 sur les thérapies combinées avec l'ADAGRASIB chez des patients atteints d'un cancer du poumon non à petites cellules avancé avec mutation KRAS G12C - Cohorte C

NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic KRAS G12C PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) None Immunotherapy Chemotherapy

Targeted therapy Targeted therapy

Centre Hospitalier Universitaire de Grenoble (La Tronche)

Mirati Thérapeutique Inc.

Phase 2 Prostate cancer #NCT06395753 #2024-511038-11-00

Étude de détermination de la dose de DEBIO 4228 chez des participants atteints d'un cancer de la prostate localement avancé/métastatique

Adenocarcinoma Metastatic Hormone-sensitive None Systemic Treatment-Naive

Centre Jean Perrin (Clermont Ferrand )

Debiopharm International SA